Bio-Rad Laboratories BIO Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenue.
The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000012208-26-000035
Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at March 31, 2026 and December 31, 2025 was $69.9 million and $62.9 million, respectively. The short-term deferred revenue balance at March 31, 2026 and December 31, 2025 was $56.3 million and $48.9 million, respectively. Deferred revenues are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets.
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bio-Rad Laboratories's deferred revenue?
- Bio-Rad Laboratories (BIO) reported deferred revenue of $69.9M in Q1 2026.
- How has Bio-Rad Laboratories's deferred revenue changed year-over-year?
- Bio-Rad Laboratories's deferred revenue increased by 2.6% year-over-year, from $68.1M to $69.9M.
- What is the long-term trend for Bio-Rad Laboratories's deferred revenue?
- Over 5 years (2020 to 2025), Bio-Rad Laboratories's deferred revenue has grown at a 0.9% compound annual growth rate (CAGR), from $60M to $62.9M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Bio-Rad Laboratories's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
